AR082313A1 - Composicion farmaceutica de combinacion para tratar enfermedades o condiciones asociadas una enfermedad o condicion respiratoria - Google Patents
Composicion farmaceutica de combinacion para tratar enfermedades o condiciones asociadas una enfermedad o condicion respiratoriaInfo
- Publication number
- AR082313A1 AR082313A1 ARP110102643A ARP110102643A AR082313A1 AR 082313 A1 AR082313 A1 AR 082313A1 AR P110102643 A ARP110102643 A AR P110102643A AR P110102643 A ARP110102643 A AR P110102643A AR 082313 A1 AR082313 A1 AR 082313A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibody
- activated form
- enhanced
- condition
- respiratory disease
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 208000023504 respiratory system disease Diseases 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 abstract 4
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 abstract 4
- 239000000243 solution Substances 0.000 abstract 4
- 101800004538 Bradykinin Proteins 0.000 abstract 3
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 abstract 3
- 102100035792 Kininogen-1 Human genes 0.000 abstract 3
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 229960001340 histamine Drugs 0.000 abstract 2
- 229960005181 morphine Drugs 0.000 abstract 2
- 238000013019 agitation Methods 0.000 abstract 1
- 239000012895 dilution Substances 0.000 abstract 1
- 238000010790 dilution Methods 0.000 abstract 1
- 238000005516 engineering process Methods 0.000 abstract 1
- 230000001632 homeopathic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39583—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials not provided for elsewhere, e.g. haptens, coenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Alternative & Traditional Medicine (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Otolaryngology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente solicitud se refiere a una composición farmacéutica de combinación que comprende a) una forma activada potenciada de un anticuerpo a bradiquinina, b) una forma activada potenciada de un anticuerpo a histamina y c) una forma activada potenciada de un anticuerpo a morfina.Reivindicación 5: La composición farmacéutica de combinación de la reivindicación 1, caracterizada porque la forma activada potenciada de un anticuerpo a la bradiquinina es un anticuerpo monoclonal, policlonal o natural. Reivindicación 12: Una composición farmacéutica para utilizarse en el tratamiento de un paciente que sufre de una enfermedad o condición respiratoria, caracterizada porque dicha composición se obtiene mediante la provisión de a) una forma activada potenciada de un anticuerpo a bradiquinina, b) una forma activada potenciada de un anticuerpo a histamina y c) una forma activada potenciada de un anticuerpo a morfina, cada una preparada por dilución consecutiva repetida y agitación múltiple de cada solución obtenida conforme a la tecnología homeopática, y luego o bien combinando las soluciones potenciadas mediante mezcla, o bien, alternativamente, impregnando una masa de portador con dicha solución combinada o con las soluciones separadamente.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2010130352/15A RU2528093C2 (ru) | 2010-07-21 | 2010-07-21 | Фармацевтическая композиция и способ лечения острых и хронических заболевания дыхательной системы и синдрома кашля |
| RU2011125992/15A RU2529783C2 (ru) | 2011-06-24 | 2011-06-24 | Лекарственное средство для лечения патологического синдрома и способ лечения острых и хронических заболеваний дыхательноый системы и синдрома кашля |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR082313A1 true AR082313A1 (es) | 2012-11-28 |
Family
ID=44899162
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110102643A AR082313A1 (es) | 2010-07-21 | 2011-07-21 | Composicion farmaceutica de combinacion para tratar enfermedades o condiciones asociadas una enfermedad o condicion respiratoria |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US8795657B2 (es) |
| EP (1) | EP2595655A2 (es) |
| JP (2) | JP2013533269A (es) |
| CN (1) | CN103200964A (es) |
| AR (1) | AR082313A1 (es) |
| AU (1) | AU2011281247B2 (es) |
| BR (1) | BR112013001297A2 (es) |
| CA (1) | CA2805978C (es) |
| CL (1) | CL2013000202A1 (es) |
| DE (1) | DE112011102412T5 (es) |
| EA (1) | EA029228B1 (es) |
| ES (1) | ES2425315R1 (es) |
| FR (1) | FR2962909A1 (es) |
| GB (1) | GB2496800B (es) |
| IT (1) | ITTO20110638A1 (es) |
| MX (1) | MX356678B (es) |
| MY (1) | MY158522A (es) |
| NZ (1) | NZ606977A (es) |
| PE (1) | PE20130387A1 (es) |
| PH (1) | PH12013500142A1 (es) |
| SG (1) | SG187579A1 (es) |
| WO (1) | WO2012010973A2 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2181297C2 (ru) * | 2000-06-20 | 2002-04-20 | Эпштейн Олег Ильич | Способ лечения патологического синдрома и лекарственное средство |
| RU2309732C1 (ru) * | 2006-03-13 | 2007-11-10 | Олег Ильич Эпштейн | Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата |
| MX2013000543A (es) | 2010-07-15 | 2013-10-28 | Oleg Iliich Epshtein | Un metodo para aumentar el efecto de una forma activa potenciada de un anticuerpo. |
| DE112011102362T5 (de) | 2010-07-15 | 2013-04-25 | Oleg Iliich Epshtein | Pharmazeutische Kombinationszusammensetzung und Verfahren zur Behandlung von Erkrankungen oder Zuständen, die mit neurodegenerativen Erkrankungen in Verbindung stehen |
| FR2962909A1 (fr) * | 2010-07-21 | 2012-01-27 | Oleg Iliich Epshtein | Composition pharmaceutique d'association et son utilisation dans des procedes pour traiter les maladies ou affections associees avec une maladie ou affection respiratoire |
| EP3693018A1 (en) * | 2010-07-21 | 2020-08-12 | Oleg Iliich Epshtein | A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders |
| CN103124741A (zh) * | 2010-07-21 | 2013-05-29 | 奥列格·伊里奇·爱泼斯坦 | 复合药物组合物以及治疗眩晕、晕动病和植物神经-血管张力障碍的方法 |
| NZ606970A (en) | 2010-07-21 | 2015-08-28 | Oleg Iliich Epshtein | A method of treating attention deficit hyperactivity disorder |
| KR20140012021A (ko) * | 2010-08-06 | 2014-01-29 | 올레그 일리치 엡쉬테인 | 감염성 질환의 치료 및 예방을 위한 제약학적 복합 조성물 및 방법들 |
| RU2013111961A (ru) | 2013-03-18 | 2014-09-27 | Олег Ильич Эпштейн | Способ определения выраженности модифицирующей активности, ассоциированной с носителем |
| RU2013111962A (ru) | 2013-03-18 | 2014-09-27 | Олег Ильич Эпштейн | Способ определения выраженности модифицирующей активности, ассоциированной с носителем |
| DE102020007979A1 (de) | 2020-12-29 | 2022-06-30 | Charité Universitätsmedizin Institut für Mikrobiologie und Infektionsimmunologie | Zusammensetzung zur Behandlung von lnfektionen mit Coronaviren |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4311897A (en) | 1979-08-28 | 1982-01-19 | Union Carbide Corporation | Plasma arc torch and nozzle assembly |
| US5741488A (en) | 1992-10-08 | 1998-04-21 | The Kennedy Institute For Rheumatology | Treatment of rheumatoid arthritis with anti-CD4 antibodies in conjunction with anti-TNF antibodies |
| IT1261849B (it) | 1993-09-02 | 1996-06-03 | Avantgarde Spa | Dispositivo medico per la somministrazione di principi attivi o farmaci a bassissimo dosaggio, in particolare di farmaci omeopatici. |
| US5629286A (en) | 1994-03-31 | 1997-05-13 | Brewitt; Barbara | Homeopathic dilutions of growth factors |
| IL110035A0 (en) | 1994-06-16 | 1994-10-07 | Tapuach Natural Technologies 1 | Homeopathic formulations |
| CN1141929C (zh) | 1996-02-12 | 2004-03-17 | O·I·伊普施廷 | 药物制剂 |
| US5834443A (en) * | 1996-05-21 | 1998-11-10 | Masiello; Domenick J. | Composition and method for treating herpes simplex |
| RU2114646C1 (ru) | 1996-09-30 | 1998-07-10 | Олег Ильич Эпштейн | Способ повышения защитных свойств организма при воздействии внешних физических факторов |
| RU2103999C1 (ru) | 1997-01-31 | 1998-02-10 | Олег Ильич Эпштейн | Способ лечения алкоголизма |
| RU2181297C2 (ru) | 2000-06-20 | 2002-04-20 | Эпштейн Олег Ильич | Способ лечения патологического синдрома и лекарственное средство |
| RU2199244C2 (ru) * | 2000-10-05 | 2003-02-27 | Самофалова Лариса Александровна | Способ получения пищевой муки масличных семян |
| RU2191602C1 (ru) | 2001-06-01 | 2002-10-27 | Эпштейн Олег Ильич | Лекарственное средство и способ лечения аллергических и псевдоаллергических реакций |
| RU2197266C1 (ru) * | 2001-06-01 | 2003-01-27 | Эпштейн Олег Ильич | Лекарственное средство и способ лечения эрозивных и воспалительных заболеваний желудочно-кишечного тракта |
| RU2206338C1 (ru) | 2001-12-07 | 2003-06-20 | Эпштейн Олег Ильич | Способ лечения синдрома кашля |
| RU2199344C1 (ru) * | 2001-12-07 | 2003-02-27 | Эпштейн Олег Ильич | Лекарственное средство и способ лечения синдрома кашля |
| RU2201255C1 (ru) | 2001-12-26 | 2003-03-27 | Эпштейн Олег Ильич | Лекарственное средство и способ регуляции сосудистого тонуса |
| RU2209083C1 (ru) | 2001-12-26 | 2003-07-27 | Эпштейн Олег Ильич | Лекарственное средство и способ лечения кашля |
| RU2199345C1 (ru) | 2001-12-26 | 2003-02-27 | Эпштейн Олег Ильич | Лекарственное средство и способ регуляции углеводного и жирового обмена |
| UA76639C2 (uk) | 2002-08-02 | 2006-08-15 | Олєг Ільіч Епштєйн | Гомеопатичний лікарський засіб та спосіб лікування еректильних дисфункцій |
| UA76638C2 (en) | 2002-08-02 | 2006-08-15 | Oleh Illich Epshtein | Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon |
| UA76641C2 (uk) | 2002-08-02 | 2006-08-15 | Олєг Ільіч Епштєйн | Гомеопатичний лікарський засіб та спосіб лікування захворювань передміхурової залози |
| WO2004082597A2 (en) | 2003-03-14 | 2004-09-30 | Nutrition Research, Inc. | Homeopathic formulations useful for treating pain and/or inflammmation |
| RU2253478C1 (ru) | 2003-10-01 | 2005-06-10 | Эпштейн Олег Ильич | Средство для потенцирования лечебных эффектов - усиления действия лекарственного вещества |
| MX2008015621A (es) * | 2006-06-06 | 2009-03-06 | Oleg Iliich Epshtein | Agente medicinal para el tratamiento de obesidad, diabetes y enfermedades relacionadas con la tolerancia deteriorada de glucosa. |
| CA2722121A1 (en) * | 2008-04-29 | 2009-11-05 | Gunvant Devichand Oswal | A homeopathic formulation |
| WO2012007847A2 (en) * | 2010-07-15 | 2012-01-19 | Oleg Iliich Epshtein | Pharmaceutical compositions and methods of treatment |
| DE112011102362T5 (de) * | 2010-07-15 | 2013-04-25 | Oleg Iliich Epshtein | Pharmazeutische Kombinationszusammensetzung und Verfahren zur Behandlung von Erkrankungen oder Zuständen, die mit neurodegenerativen Erkrankungen in Verbindung stehen |
| US8637030B2 (en) | 2010-07-15 | 2014-01-28 | Oleg I. Epshtein | Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract |
| DE112011102350T5 (de) | 2010-07-15 | 2013-04-18 | Oleg Iliich Epshtein | Pharmazeutische Kombinationszusammensetzung und Verfahren zur Behandlung von Störungen des Urogenitalsystems |
| CN103124741A (zh) | 2010-07-21 | 2013-05-29 | 奥列格·伊里奇·爱泼斯坦 | 复合药物组合物以及治疗眩晕、晕动病和植物神经-血管张力障碍的方法 |
| EP3693018A1 (en) * | 2010-07-21 | 2020-08-12 | Oleg Iliich Epshtein | A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders |
| FR2962909A1 (fr) * | 2010-07-21 | 2012-01-27 | Oleg Iliich Epshtein | Composition pharmaceutique d'association et son utilisation dans des procedes pour traiter les maladies ou affections associees avec une maladie ou affection respiratoire |
| KR20140012021A (ko) | 2010-08-06 | 2014-01-29 | 올레그 일리치 엡쉬테인 | 감염성 질환의 치료 및 예방을 위한 제약학적 복합 조성물 및 방법들 |
-
2011
- 2011-07-15 FR FR1156475A patent/FR2962909A1/fr not_active Withdrawn
- 2011-07-15 CN CN2011800455711A patent/CN103200964A/zh active Pending
- 2011-07-15 IT IT000638A patent/ITTO20110638A1/it unknown
- 2011-07-15 SG SG2013004825A patent/SG187579A1/en unknown
- 2011-07-15 JP JP2013520239A patent/JP2013533269A/ja active Pending
- 2011-07-15 MX MX2013000806A patent/MX356678B/es active IP Right Grant
- 2011-07-15 AU AU2011281247A patent/AU2011281247B2/en not_active Ceased
- 2011-07-15 ES ES201390008A patent/ES2425315R1/es active Pending
- 2011-07-15 PE PE2013000107A patent/PE20130387A1/es not_active Application Discontinuation
- 2011-07-15 NZ NZ606977A patent/NZ606977A/en not_active IP Right Cessation
- 2011-07-15 US US13/135,884 patent/US8795657B2/en active Active
- 2011-07-15 CA CA2805978A patent/CA2805978C/en not_active Expired - Fee Related
- 2011-07-15 EP EP11778681.4A patent/EP2595655A2/en not_active Ceased
- 2011-07-15 BR BR112013001297A patent/BR112013001297A2/pt not_active Application Discontinuation
- 2011-07-15 EA EA201300131A patent/EA029228B1/ru not_active IP Right Cessation
- 2011-07-15 DE DE112011102412T patent/DE112011102412T5/de not_active Withdrawn
- 2011-07-15 GB GB1302926.9A patent/GB2496800B/en not_active Expired - Fee Related
- 2011-07-15 WO PCT/IB2011/002346 patent/WO2012010973A2/en not_active Ceased
- 2011-07-15 PH PH1/2013/500142A patent/PH12013500142A1/en unknown
- 2011-07-15 MY MYPI2013000232A patent/MY158522A/en unknown
- 2011-07-21 AR ARP110102643A patent/AR082313A1/es unknown
-
2013
- 2013-01-21 CL CL2013000202A patent/CL2013000202A1/es unknown
-
2014
- 2014-07-11 US US14/328,792 patent/US20150023985A1/en not_active Abandoned
-
2016
- 2016-07-01 JP JP2016131753A patent/JP2016216479A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| GB2496800A (en) | 2013-05-22 |
| SG187579A1 (en) | 2013-03-28 |
| PE20130387A1 (es) | 2013-03-30 |
| AU2011281247B2 (en) | 2015-07-30 |
| GB201302926D0 (en) | 2013-04-03 |
| WO2012010973A3 (en) | 2012-04-26 |
| ES2425315R1 (es) | 2014-09-08 |
| EP2595655A2 (en) | 2013-05-29 |
| EA029228B1 (ru) | 2018-02-28 |
| ES2425315A2 (es) | 2013-10-14 |
| MX356678B (es) | 2018-06-08 |
| CA2805978C (en) | 2016-06-28 |
| BR112013001297A2 (pt) | 2017-11-21 |
| MX2013000806A (es) | 2013-10-28 |
| FR2962909A1 (fr) | 2012-01-27 |
| CN103200964A (zh) | 2013-07-10 |
| JP2016216479A (ja) | 2016-12-22 |
| ITTO20110638A1 (it) | 2012-01-22 |
| US20120225074A1 (en) | 2012-09-06 |
| EA201300131A1 (ru) | 2013-11-29 |
| DE112011102412T5 (de) | 2013-07-04 |
| CA2805978A1 (en) | 2012-01-26 |
| AU2011281247A1 (en) | 2013-03-14 |
| MY158522A (en) | 2016-10-14 |
| PH12013500142A1 (en) | 2013-03-11 |
| CL2013000202A1 (es) | 2015-01-16 |
| US20150023985A1 (en) | 2015-01-22 |
| WO2012010973A2 (en) | 2012-01-26 |
| US8795657B2 (en) | 2014-08-05 |
| GB2496800B (en) | 2018-05-23 |
| JP2013533269A (ja) | 2013-08-22 |
| NZ606977A (en) | 2015-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR082313A1 (es) | Composicion farmaceutica de combinacion para tratar enfermedades o condiciones asociadas una enfermedad o condicion respiratoria | |
| AR082245A1 (es) | Composicion farmaceutica de combinacion para tratar enfermedades funcionales o condiciones de tracto gastrointestinal | |
| MX2024010140A (es) | Nuevos metodos. | |
| MY178654A (en) | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or an anti-adm non-ig protein scaffold for use in therapy | |
| MY199017A (en) | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or an anti-adm non-ig scaffold for use in therapy | |
| EA201490546A1 (ru) | Замещенные аннелированные пиримидины и их применение | |
| EA201291336A1 (ru) | Замещенные 5-фтор-1н-пиразолопиридины и их применение | |
| EA201490004A1 (ru) | Применение bifidobacterium lactis bl-04 для лечения заболеваний дыхательных путей | |
| AR059922A1 (es) | Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos | |
| CO6341486A2 (es) | Tratamiento y profilaxis de amiloidosis | |
| NZ601580A (en) | Therapeutic methods using anti-cd200 antibodies | |
| EA201390060A1 (ru) | Аннелированные пиримидины и триазины и их применение для лечения и/или профилактики сердечно-сосудистых заболеваний | |
| EA033400B1 (ru) | Антитело против cd3 и его применение | |
| MX374870B (es) | Inhalador de polvo seco. | |
| MY191040A (en) | Therapy involving antibodies against claudin 18.2 for treatment of cancer | |
| UA118453C2 (uk) | Спосіб лікування пухлин у пацієнта | |
| GT201200318A (es) | Anticuerpos hacia gdf8 humano | |
| EA201391581A1 (ru) | Способы лечения болезни альцгеймера, болезни хантингтона, аутизма и других расстройств | |
| AR097178A1 (es) | Diagnóstico y terapias anticáncer que comprenden células madre cancerosas | |
| RU2018145985A (ru) | Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений | |
| BR112013000841A2 (pt) | composições farmacêuticas, métodos de tratamento da obesidade e distúrbios metabólicos relacionados, de redução da massa corpórea de mamífero, do crescimento da massa corpórea de mamífero, do consumo de comida em mamífero, de trtamento de paciente de adicção de substância psicoativa, de adicção de substância psicoativa e uso de forma ativada-potencializada de anticorpo para receptor de canabinoide humano. | |
| EA201390506A1 (ru) | Полипептиды, которые связывают компонент с5 комплемента человека | |
| EA201591618A1 (ru) | Замещенные имидазопиридазины | |
| MX356808B (es) | Uso de una composición farmacéutica que comprende un anticuerpo anti-il-1a para el tratamiento de la caquexia. | |
| EP2670435A1 (en) | Use of anti-dkk1 monoclonal antibody for treatment of liver cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |